CY1109036T1 - Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης - Google Patents

Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης

Info

Publication number
CY1109036T1
CY1109036T1 CY20091100429T CY091100429T CY1109036T1 CY 1109036 T1 CY1109036 T1 CY 1109036T1 CY 20091100429 T CY20091100429 T CY 20091100429T CY 091100429 T CY091100429 T CY 091100429T CY 1109036 T1 CY1109036 T1 CY 1109036T1
Authority
CY
Cyprus
Prior art keywords
bvdv
attenuated
plague viruses
vanished
virus
Prior art date
Application number
CY20091100429T
Other languages
Greek (el)
English (en)
Inventor
Gregor Meyers
Andreas Ege
Christiane Meyer
Freyburg Martina Von
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109036(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CY1109036T1 publication Critical patent/CY1109036T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20091100429T 2004-05-19 2009-04-10 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης CY1109036T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004025452A DE102004025452A1 (de) 2004-05-19 2004-05-19 Vakzine enthaltend BVDV
EP05741681.0A EP1751276B9 (en) 2004-05-19 2005-05-18 Vaccine comprising an attenuated pestivirus

Publications (1)

Publication Number Publication Date
CY1109036T1 true CY1109036T1 (el) 2014-07-02

Family

ID=34967522

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20091100429T CY1109036T1 (el) 2004-05-19 2009-04-10 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
CY2015021C CY2015021I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
CY2015022C CY2015022I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
CY2015023C CY2015023I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2015021C CY2015021I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
CY2015022C CY2015022I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
CY2015023C CY2015023I2 (el) 2004-05-19 2015-06-19 Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης

Country Status (26)

Country Link
EP (1) EP1751276B9 (enExample)
JP (2) JP5006782B2 (enExample)
KR (1) KR100908798B1 (enExample)
CN (2) CN1989240B (enExample)
AR (2) AR049176A1 (enExample)
AT (1) ATE420949T1 (enExample)
AU (1) AU2005243488B2 (enExample)
BR (1) BRPI0510396B1 (enExample)
CA (1) CA2561719C (enExample)
CY (4) CY1109036T1 (enExample)
DE (2) DE102004025452A1 (enExample)
DK (1) DK1751276T5 (enExample)
ES (1) ES2321210T3 (enExample)
FR (3) FR15C0044I2 (enExample)
HU (2) HUS1500031I1 (enExample)
LU (3) LU92748I2 (enExample)
ME (1) ME01119B (enExample)
MX (1) MXPA06013298A (enExample)
NL (3) NL300745I1 (enExample)
NZ (1) NZ552088A (enExample)
PL (1) PL1751276T3 (enExample)
PT (1) PT1751276E (enExample)
RS (1) RS50753B9 (enExample)
SI (1) SI1751276T1 (enExample)
UY (1) UY28905A1 (enExample)
WO (1) WO2005111201A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179473B2 (en) 1998-06-05 2007-02-20 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
US7135561B2 (en) 2001-09-06 2006-11-14 Boehringer Ingelheim Vetmedica Gmbh Infectious bovine viral diarrhea virus clone
UY29915A1 (es) * 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
WO2008034857A1 (en) 2006-09-22 2008-03-27 Intervet International B.V. Pestivirus mutant for use in a vaccine
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
EP2362780B1 (en) 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
US8846054B2 (en) 2009-01-09 2014-09-30 Boehringer Ingelheim Vetmedica, Inc. Method of treating pregnant cows and/or heifers
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
ES2606605T3 (es) 2010-09-21 2017-03-24 Intervet International B.V. Vacuna para el BVDV
JP6589159B2 (ja) * 2014-04-01 2019-10-16 共立製薬株式会社 新規ネコモルビリウイルス株、不活化ワクチン製剤、並びにネコモルビリウイルス感染症予防方法
DK3146042T3 (da) * 2014-05-23 2019-09-30 Boehringer Ingelheim Vetmedica Gmbh Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
CN105779499B (zh) * 2016-03-23 2019-11-19 江苏科技大学 重组杆状病毒和其应用及构建该重组杆状病毒的载体
CN107823639B (zh) * 2017-11-10 2020-10-02 齐鲁动物保健品有限公司 牛病毒性腹泻病毒灭活疫苗及其制备方法
CN108707190B (zh) * 2018-04-18 2021-07-13 中国科学院武汉病毒研究所 猪瘟病毒ns5b蛋白保真度突变体及其应用
CN114853912B (zh) * 2022-05-24 2023-06-13 中国农业科学院兰州兽医研究所 一种牛病毒性腹泻病毒e2-e0融合蛋白、制备方法及应用
CN115960847B (zh) * 2023-01-11 2024-06-14 青岛大学 小分子依赖的内含肽自剪接系统在制备减毒活疫苗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) * 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
EP1104676A1 (en) * 1999-11-30 2001-06-06 Boehringer Ingelheim Vetmedica Gmbh Safe attenuated bovine viral diarrhea viruses for use in pregnant cows
CA2363493C (en) * 2000-11-22 2006-06-06 Xuemei Cao Attenuated forms of bovine viral diarrhea virus
DE10143813A1 (de) * 2001-09-06 2003-04-10 Boehringer Ingelheim Vetmed Infektiöser Rindervirusdiarrhoe-Virusklon

Also Published As

Publication number Publication date
CA2561719A1 (en) 2005-11-24
FR15C0042I1 (fr) 2015-07-24
AU2005243488A1 (en) 2005-11-24
LU92747I2 (fr) 2015-11-02
CY2015023I2 (el) 2024-02-16
WO2005111201A1 (en) 2005-11-24
FR15C0044I1 (fr) 2015-07-24
BRPI0510396A (pt) 2007-11-13
CY2015022I2 (el) 2024-02-16
FR15C0043I1 (fr) 2015-07-24
NL300745I2 (enExample) 2016-01-26
BRPI0510396B1 (pt) 2020-08-18
FR15C0042I2 (fr) 2018-11-16
JP2012061001A (ja) 2012-03-29
CY2015022I1 (el) 2020-05-29
NZ552088A (en) 2009-10-30
FR15C0043I2 (fr) 2016-05-27
JP5562316B2 (ja) 2014-07-30
FR15C0044I2 (fr) 2016-05-27
SI1751276T1 (sl) 2009-06-30
CN1989240B (zh) 2013-07-31
MXPA06013298A (es) 2007-05-07
CA2561719C (en) 2015-01-27
ES2321210T9 (es) 2020-11-04
RS50753B9 (sr) 2020-08-31
JP2007537740A (ja) 2007-12-27
AR104448A2 (es) 2017-07-19
AU2005243488B2 (en) 2011-07-07
KR20070012862A (ko) 2007-01-29
NL300743I1 (enExample) 2016-01-26
CY2015021I2 (el) 2023-11-15
LU92748I2 (fr) 2015-11-02
CN103352030B (zh) 2018-08-10
DK1751276T3 (da) 2009-05-18
UY28905A1 (es) 2005-12-30
PT1751276E (pt) 2009-02-24
EP1751276A1 (en) 2007-02-14
EP1751276B9 (en) 2020-05-27
JP5006782B2 (ja) 2012-08-22
LU92749I2 (fr) 2015-11-02
DE102004025452A1 (de) 2006-01-19
CN103352030A (zh) 2013-10-16
CY2015023I1 (el) 2020-05-29
HUS1500031I1 (hu) 2019-11-28
KR100908798B1 (ko) 2009-07-22
CY2015021I1 (el) 2020-05-29
AR049176A1 (es) 2006-07-05
RS50753B (sr) 2010-08-31
NL300743I2 (enExample) 2016-01-26
ME01119B (me) 2013-03-20
DE602005012381D1 (de) 2009-03-05
EP1751276B1 (en) 2009-01-14
DK1751276T5 (da) 2020-07-20
NL300744I2 (enExample) 2016-01-26
NL300744I1 (enExample) 2016-01-26
PL1751276T3 (pl) 2009-06-30
NL300745I1 (enExample) 2016-01-26
ATE420949T1 (de) 2009-01-15
CN1989240A (zh) 2007-06-27
HUS1500033I1 (hu) 2015-07-28
ES2321210T3 (es) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1118958T1 (el) Μεθοδοι και συνθεσεις για ζωντανους εξασθενημενους ιους
CO6160335A2 (es) Vacuna
MX341842B (es) Virus de la influenza capaces de infectar canidos y usos de los mismos.
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
CY1118003T1 (el) Αναπτυξη συστατικων εμβολιου ιου δαγκειου
DE60228971D1 (de) Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
AR049176A1 (es) Vacuna que comprende un pestivirus atenuado
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ATE513561T1 (de) Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien
NO20043707L (no) Nye immuno effektor forbindelser
EA200301151A1 (ru) Вакцина против натуральной оспы
DE69637640D1 (de) N und anwendungen